Is Z' factor the best assessment for the quality of cellular assays delivering higher content?

в

Elizabeth P. Roquemore, Sam Murphy, *Stephen J. Capper, Suzanne M. Hancock, Elaine Adie, Molly Price-Jones, Stephen Game & Stuart Swinburne Amersham Biosciences UK Limited, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA England

Abstract

As high throughput imaging systems, analysis algorithms and associated cellular assays have begun to be used in profiling and secondary analysis, scientists have used tools derived from primary screening such as Z factor to assess assay quality. Image-based cellular assays may be better suited to lead profiling, where the needs are different and modified criteria should be applied in assessing assay quality. We ask the question what statistical metrics most accurately reflect the nature and use of cell-based assays in lead profiling? We present data from a variety of such assays we have developed, such as GFP transfocation assays, including simple Z' factor analysis and propose multiple statistical approaches to assess assay quality that may be better suited to high information content assays.

Introduction

We have developed a number of live-cell translocation assays that are compatible with high-throughput micro-imaging platforms such as the IN Cell Analyzer 3000 and the IN Cell Analyzer 1000. To assess assay quality during assay development and for subsequent QA, we initially used the well known measure of assay performance, Z' factor. While Z' factor is of value in assessing the size of the reading window for a screening assay, we observed that in some cases Z' factor analysis obscured meaningful differences in assay performance. Consequently, we have explored the use of signal-to-noise as a statistical metric more appropriate to the needs of image-based cellular assays.

Results

A common characteristic of cell-based assays (in contrast to many in vitro assays) is that the statistical variation associated with control and treated sample populations is often significantly different (Figure 1). This phenomenon may be both cell type- and target-dependent. The causes may be manifold, but inherent cell population heterogeneity, particularly with respect to cell cycle position, and methods of image analysis have been noted as potential contributory factors.



Figure 1: Magnitude of standard deviation (SD) associated with negative and positive controls is not always equal. Data are from a CypHerTM assay for agonist-induced activation and internalization of the β 2-Adrenergic Receptor.

Assay performance assessments based on a signal-to-noise (S:N) method that does not take into account the standard deviation of both control and treated samples will be prone to error. For example, a signal-to-noise metric still cited in screening literature for assessment of *in vitro* assays involves dividing the magnitude of assay response by the standard deviation of the control (untreated) sample: $-\mu_n$ Method A

μ = mean signal σ = standard deviation p = positive control n = negative control

where

We used this S:N calculation to assess assay performance of eight replicate plates imaged and analyzed using the IN Cell Analyzer 1000. The S:N values obtained using this method varied greatly (Figure 2, S:N, method A).

By contrast, S:N values were much more consistent between replicate plates (Figure 2, method B) when we used an alternative method for S:N calculation that takes into account variation of both the control and responding sample populations:



Figure 2: Variation of assay performance as assessed by different methods of S:N calculation. Data are from a live-cell GFP-MAPKAP-k2 translocation assay (code 25-8008-82) performed on the IN Cell Analyzer 1000.

During assay optimization, S:N (method B) can be a more sensitive indicator of assay performance than the Z' factor. This is demonstrated by the data shown in Figure 3, where Z' factor and S:N values of the same assay performance data are compared.





Figure 3: Affect of varying a primary analysis parameter (cytoplasmic sampling ring dilation factor) on the assay window of an antagonistformat GFP_MAPKAP-K2 assay. A. Increasing the dilation factor increases the assay magnitude of response (MOR) but also leads to an increase in noise associated with both control and treated samples. B. Comparison of S:N and Z' factor values from the same data set as in A. S:N analysis indicates that a dilation factor of 7 provides the largest assay window, while Z' factor analysis of the same dataset fails to distinguish adequately between dilation factors of 5 and 7.

Since both S:N (method B) and Z' factor are based on the same variables, there is a defined relationship between the two metrics, assuming for simplicity that standard deviation of the positive and negative controls are equal:

$$Z' = 1 - \frac{3\sigma_p + 3\sigma_n}{|\mu_p - \mu_n|} \qquad Z' = 1 - \frac{4.24}{S:N}$$

ere S:N = signal to noise (method B) μ = mean signal σ = standard deviation p = positive control n = neative control

Although the assumption that standard deviations of positive and negative controls are equal is not always true, we have observed that actual data correspond fairly well to this model relationship. A plot of the relationship between S:N (method B) and Z' factor is shown in Figure 4 together with the actual data from an EGFP-NFATc1 translocation assay we have developed. The actual data show a very good correlation to the theoretical curve.



NFAT Assay:

Figure 4: Correlation between Z' factor and S:N. The points are actual values from a performance trial of the EGFP-NFATc1 assay (code 25-8010-42) read on the IN Cell Analyzer 3000. The curve is the theoretical curve for the predicted relationship. As the results in Figure 5 demonstrate, this relationship holds true for a variety of cell-based assays, including FYVE, AKT-1, PLC&-PH, Rac-1, MAPKAP-k2, SMAD2 and NFATc1 (all GFP-

based assays performed in live cells).





It can be seen from Figures 4 and 5 that, while Z' factor may be a sensitive indicator of assay performance at the lower end of the performance scale (i.e. Z' < 0.5, S:N < 8), S:N may be a more sensitive indicator at the higher end of the performance scale. As S:N increases, Z' factor approaches 1 asymptotically, making it an increasingly less sensitive measure of performance improvement. For example, the arrows in Figure 5 indicate two assays whose performance could not confidently be distinguished on the basis of Z' factor, but which have distinctly different S:N values. Both metrics of assay performance (Z' factor and S:N) therefore may be useful in optimizing assay performance.

Ref: Zhang et al J. Biomol. Screening 4, 67-73, 1999.

Acknowledgement: The authors gratefully acknowledge members of the Molecular Cell Biology Department, Amersham Biosciences, Cardiff, for providing data from a range of cell-based asssays. We also extend our thanks to Bob Nadon (McGill University) for his expert technical advice.

CONCLUSION

High information-content image-based cellular assays have properties distinct from more traditional screening assays, and their evaluation may therefore require adoption of additional statistical metrics.

S:N calculations that take into account standard deviation of both positive and negative controls are less prone to error than those derived from the standard deviation of negative controls only.

Both S:N and Z' factor may provide valuable information during assay and image analysis optimization.

The theoretical relationship between Z' factor and S:N (method B) has been shown to be well supported by the results of several cell-based assays performed using IN Cell Analyzer 3000 and IN Cell Analyzer 1000.

©Amersham Biosciences Limited 2003 - All rights reserved. Amersham Biosciences. Amersham Place Little Chalfont Backinghamshire England U.K. HP 79NA. Amersham Biosciences AD 85-751 84 Uppsala Sweden. Amersham Biosciences Corp 800 Centennial Avenue PO Box 1327 Piscutaway NJ 08855 USA. Amersham Biosciences Europe GmbH. Munzinger Strasse, 9D.-79111, Freiburg, Germany.

Cyplete is a trademark of Amersham Biosciences Limited. Amersham and Amersham Biosciences are trademarks of Amersham Disociences. The GPP assays are the subject of pattern GB 2374886. The and pattern applications PETCBIO104563, USB90976701 and PETCBE024554 in the name of Amersham Biosciences, and were developed under license from Biomage AS ander patterns US 6 172 188, EP 851874, US 5 958 713 and EP 0815257, and under international pattern applications PCTBP0106848 and other patterns applications. Envirogen IP biodings in te (fromerly Aurone Biosciences Corporation) under pattern US 5 62 048, US 5 7707 90, US 5 948 373, US 5 968 731, US 5 066 737, US 6 067 70, US 6 064 731, US 6 064 70, US 6 067 70, US 6 064 731, US 6 064 70, US 6 064 70, US 6 064 731, US 6 064 70, US 6 064 207, US 6 090 919, US 6 124 128, US 6 319 909, US 6 403 374, EP0804457, EP1104769, IP238522 and other pending and foreign patent applications, University of Florida under US patents 5968 750, 5 874 304, 5 797 537, 6 050 192 and other pending and foreign patent applications; Columbia University under US patent Nos. 5 491 084 and 6 146 826. Rights to use this product, as configured, are limited to internal use for screening, development and discovery of therapeutic products. NOT FOR JACKOSTIC USE ON THREAPEUTCL USE IN HUMANS 0R ANIMALS. No other rights are conveyed. All goods and services are sold subject to terms and conditions of sale of the company within the Amersham Biosciences group which supplies them. A copy of these terms and conditions of request in the available on request.

CyDye: this product or portions thereof is manufactured under license from Caenegie Mellon University under US patent number US 5 268 486 and other patents pending . Some of these products may only be available to collaborators and customers within certain of our technology access programs.

This poster was presented at High-Content Analysis 29-30 Jan 2004 San Francisco, CA (Data also presented at SBS Sept 2003, Portland, Oregon, USA) * To whom all correspondence should be addressed.

